126 related articles for article (PubMed ID: 3502571)
1. Circulating immune complexes in breast cancer patients.
Croce MV; Pasqualini RS; Segal-Eiras A
Medicina (B Aires); 1987; 47(4):371-6. PubMed ID: 3502571
[No Abstract] [Full Text] [Related]
2. Ferritin levels and circulating immune complexes in patients with solid tumors.
Celada A; Barnet M; Aguado MT; Cruchaud A; Lambert PH
Bull Cancer; 1982; 69(1):22-7. PubMed ID: 6978747
[TBL] [Abstract][Full Text] [Related]
3. The classical complement pathway: mechanism of activation of the first component by antigen-antibody complexes.
Loos M
Prog Allergy; 1982; 30():135-92. PubMed ID: 7041131
[No Abstract] [Full Text] [Related]
4. [Circulating immune complexes in breast cancer].
Abecassis J; Petit JC; Eber M; Klein T; Rodier D; Janser JC; Methlin G
Bull Cancer; 1985; 72(1):42-7. PubMed ID: 3872691
[TBL] [Abstract][Full Text] [Related]
5. [The liquid phase C1q binding assay and its clinical application].
Cheng PZ; Dong Y; Zhang NZ; Ji D; Dai X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1987 Feb; 9(1):69-71. PubMed ID: 2954693
[No Abstract] [Full Text] [Related]
6. [Circulating immune complexes: optimization and characteristics of the C1q(I125) fixation test].
Caillot G; Lamelin JP; Hartmann DJ; Ville G
Pathol Biol (Paris); 1984 Nov; 32(9):931-7. PubMed ID: 6334270
[TBL] [Abstract][Full Text] [Related]
7. [Correlations between complement degradation products and circulating immune complexes in human glomerulonephritis].
Coppo R; De Marchi M; Alloatti S; Segoloni G; Giacchino F; Quarello F; Roccatello D; Bulzomi MR; Piccoli G
Minerva Nefrol; 1979; 26(3):243-50. PubMed ID: 318057
[No Abstract] [Full Text] [Related]
8. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
Pearlstein E; Sorvillo J; Gigli I
J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
[TBL] [Abstract][Full Text] [Related]
9. Detection of circulating immune complexes in patients with squamous cell carcinoma of the oral cavity.
Mukhopadhyaya R; Rao RS; Fakih AR; Gangal SG
J Clin Lab Immunol; 1986 Dec; 21(4):189-93. PubMed ID: 3494132
[TBL] [Abstract][Full Text] [Related]
10. [Circulating immune complexes following long-term physical work].
Dufaux B; Höffken K; Order U
Fortschr Med; 1985 Jan; 103(4):59-61. PubMed ID: 3871721
[No Abstract] [Full Text] [Related]
11. [Complement components, whole complement activity, and circulating immune complexes in neoplastic diseases].
Takada K; Morishita M; Sugiura T; Suzuki M; Torii Y; Ichimura K; Hashigami H; Toshikawa K; Ina Y; Yamamoto M; Oyama A; Urata A
Gan No Rinsho; 1983 Apr; 29(4):A-19, 293-6. PubMed ID: 6602233
[TBL] [Abstract][Full Text] [Related]
12. Circulating immune complexes detected by C1q solid phase assay in leprosy.
Nuti M; D'Amelio R; Seminara R; Milano CF; Palmisano L; Aiuti F
Int J Lepr Other Mycobact Dis; 1981 Mar; 49(1):27-30. PubMed ID: 6972924
[TBL] [Abstract][Full Text] [Related]
13. [Determination of immune complex levels--with special reference to C1q and the anti-antibody method].
Kasukawa R
Rinsho Byori; 1986 Oct; Spec No 69():35-44. PubMed ID: 3543438
[No Abstract] [Full Text] [Related]
14. The correlation between insulin antibodies and circulating immune complexes in diabetics with and without microangiopathy.
Di Mario U; Ventriglia L; Iavicoli M; Guy K; Andreani D
Clin Exp Immunol; 1983 Jun; 52(3):575-80. PubMed ID: 6603299
[TBL] [Abstract][Full Text] [Related]
15. [Use of the C1q binding assay in the analysis of immune complexes: personal experiences with its clinical use and future prospectives].
Corvetta A; Spaeth PJ; Panico F; Ghirelli PA; Orecchioni F; Danieli G
G Clin Med; 1983; 64(9-10):337-48. PubMed ID: 6198235
[No Abstract] [Full Text] [Related]
16. Critical aspects of the 125I-C1q binding assay for detecting immune complexes in tumor patients.
Krieger G; Bause I; Kneba M; Kehl A; Nagel GA
J Clin Lab Immunol; 1984 Jun; 14(2):87-92. PubMed ID: 6611419
[TBL] [Abstract][Full Text] [Related]
17. [Determination of immunocomplexes. III. A method using a solid surface for immunocomplex binding and use of C1q subcomponent of the first complement component (C1q SP)].
Votruba T; Rákosník P
Cesk Epidemiol Mikrobiol Imunol; 1988 Feb; 37(1):15-22. PubMed ID: 2967114
[No Abstract] [Full Text] [Related]
18. Immune complexes in systemic sclerosis; detection by C1q binding, K-cell inhibition and Raji cell radioimmunoassays.
Hughes P; Cunningham J; Day M; Fitzgerald JC; French MA; Wright JK; Rowell NR
J Clin Lab Immunol; 1983 Mar; 10(3):133-8. PubMed ID: 6601718
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.
Mooney NA; Hay FC; Poulton TA
Clin Exp Immunol; 1983 Jun; 52(3):561-8. PubMed ID: 6603297
[TBL] [Abstract][Full Text] [Related]
20. Immune complexes in diabetes mellitus: studies of complement utilisation and tissue deposition.
Charlesworth JA; Campbell LV; Catanzaro R; Pussell BA; Pasterfield GV; Peake P
J Clin Lab Immunol; 1982 Sep; 8(3):163-8. PubMed ID: 6752415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
